Any current/future new fundraising through debt or equity?

Glenmark Pharmaceuticals does not currently have plans for significant fundraising through equity or large stake sales. There is a mandated sell-down of 7% to 8% stake in Glenmark Life Sciences by August 2024, as per regulatory requirements. Any proceeds from the stake sale are not aimed at debt repayment but to maintain required public shareholding. The company expects to manage debt payments and reduction primarily through internal cash generation without major asset sales. Debt is currently at about Rs. 3,000 crore net, with efforts ongoing to reduce it over the next two years. Rising inter

Any current/future capex/capital investment/strategic investment?

Glenmark Pharmaceuticals is targeting consolidated CAPEX of Rs. 600 crore to Rs. 700 crore for FY'24. (Page 7) Total asset addition in Q1 FY'24 was Rs. 127.5 crore (tangible assets ~Rs. 108 crore, intangible ~Rs. 19.5 crore). (Page 7) Investment focus areas include Respiratory, Complex Injectables, and other pipeline assets to fuel future growth. (Page 12) The company is undertaking remediation works for US and India facilities with minimal further cost expected, reflecting ongoing capital and operational investments for compliance and business continuity. (Pages 8, 16) Glenmark aims to priori

Future growth expectations in sales/revenue/volumes?

Glenmark aims for consolidated revenue growth of 10%-11% in FY'24. Europe business expected to grow 15%-20% sustainably, potentially reaching $300 million in revenue. U.S. market targeted to maintain mid-single-digit growth, aiming for around $100 million per quarter with 8-10 product launches planned in FY'24. India business projected to grow in the single digits, excluding divestments and NLEM impact, with potential upside from strong franchises in Dermatology (#2), Respiratory (#2), and Cardiac (#5). Ryaltris inhaler sales are ahead of initial $40-$45 million revenue guidance for FY'24; exp

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark aims for consolidated revenue growth of 10% to 11% in FY'24. Consolidated EBITDA margin target is 19% to 20%+. R&D investment planned at 8% to 8.5% of revenue. Europe business expected to grow 15%-20% on a sustained basis, projected to be a $300 million business this year. U.S. business to continue mid-single-digit growth with new product launches; sustained revenue at around $100 million per quarter. India business expected to grow in single digits, with strong franchises in Dermatology (#2) and Respiratory (#2). Focus on partnering pipeline assets to drive future growth. Cost of rem

IN US

Sale is live|00:00:00left today

Glenmark Pharmaceuticals LtdQ2 FY24Pharmaceuticals & Biotechnology

Glenmark Pharmaceuticals Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,225P/E: 24.3Market Cap: ₹65.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

→Glenmark aims for consolidated revenue growth of 10%-11% in FY'24.
→Europe business expected to grow 15%-20% sustainably, potentially reaching $300 million in revenue.
→U.S. market targeted to maintain mid-single-digit growth, aiming for around $100 million per quarter with 8-10 product launches planned in FY'24.
→India business projected to grow in the single digits, excluding divestments and NLEM impact, with potential upside from strong franchises in Dermatology (#2), Respiratory (#2), and Cardiac (#5).
→Ryaltris inhaler sales are ahead of initial $40-$45 million revenue guidance for FY'24; expected to grow to $150 million over time.
→Pipeline products in Respiratory, Oncology, and complex injectables foster longer-term growth.
→Remediation efforts are nearly complete, minimizing future costs and supporting operational stability.
→Focus on reducing net debt gradually as business grows and cash flows improve.

Margin guidance

→Glenmark aims for consolidated revenue growth of 10% to 11% in FY'24.
→Consolidated EBITDA margin target is 19% to 20%+.
→R&D investment planned at 8% to 8.5% of revenue.
→Europe business expected to grow 15%-20% on a sustained basis, projected to be a $300 million business this year.
→U.S. business to continue mid-single-digit growth with new product launches; sustained revenue at around $100 million per quarter.
→India business expected to grow in single digits, with strong franchises in Dermatology (#2) and Respiratory (#2).
→Focus on partnering pipeline assets to drive future growth.
→Cost of remediation is largely complete; minimal future expenses expected which should support profitability.
→Working capital and debt reduction are priorities to improve financial health.
→Overall, Glenmark is optimistic to meet or exceed its operating earnings and EPS guidance for FY'24.

3 more insights locked — sign up free to unlock

Fundraise plans

→Glenmark Pharmaceuticals does not currently have plans for significant fundraising through equity or large stake sales.
→There is a mandated sell-down of 7% to 8% stake in Glenmark Life Sciences by August 2024, as per regulatory requirements.
→Any proceeds from the stake sale are not aimed at debt repayment but to maintain required public shareholding.
→The company expects to manage debt payments and reduction primarily through internal cash generation without major asset sales.
→Debt is currently at about Rs. 3,000 crore net, with efforts ongoing to reduce it over the next two years.
→Rising interest costs are mainly due to global rate hikes (LIBOR increase from 1.5% to 5.5%), not increased debt quantum.
→Minimal remediation costs may continue but are not expected to materially impact finances or trigger fundraising needs.

Order book

The provided transcript from Glenmark Pharmaceuticals' Q1 FY'24 earnings call does not explicitly mention details about the current or expected order book or pending orders. However, relevant insights related to growth and business outlook include: - Europe business targeting 25%-30% growth, expecting to become a $300 million business this year. - Sustained Europe growth expected at 15%-20% going forward. - U.S. market stable around $100 million per quarter with mid-single-digit growth. - India business expected to grow in single digits despite some short-term challenges. - Ongoing launches and filings (8-12 products) expected to fuel U.S. growth. - Key pipeline focus includes Respiratory, Injectable, Oncology assets, and ICHNOS pipeline. - Ryaltris sales progressing well, targeting $40-$45 million revenues this fiscal, with further launches upcoming in Brazil, Mexico, China, major European markets. No explicit order book or backlog details are disclosed in this transcript.

Capex plans

→Glenmark Pharmaceuticals is targeting consolidated CAPEX of Rs. 600 crore to Rs. 700 crore for FY'24. (Page 7)
→Total asset addition in Q1 FY'24 was Rs. 127.5 crore (tangible assets ~Rs. 108 crore, intangible ~Rs. 19.5 crore). (Page 7)
→Investment focus areas include Respiratory, Complex Injectables, and other pipeline assets to fuel future growth. (Page 12)
→The company is undertaking remediation works for US and India facilities with minimal further cost expected, reflecting ongoing capital and operational investments for compliance and business continuity. (Pages 8, 16)
→Glenmark aims to prioritize free cash flow generation alongside closing an out-licensing deal, which could signal future strategic investments or partnerships. (Page 7)

How does Glenmark Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Glenmark Pharmaceuticals Ltd

See full Pharmaceuticals & Biotechnology sector rankings